Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Interest Expenses (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Interest Expenses for 4 consecutive years, with $1708.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses rose 16.43% to $1708.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $6141.0, a 48.55% decrease, with the full-year FY2024 number at $7912.0, down 99.65% from a year prior.
  • Interest Expenses was $1708.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $1221.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.2 million in Q3 2023 to a low of -$1.6 million in Q4 2022.
  • A 4-year average of $57467.5 and a median of $1708.0 in 2025 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 7442.14% in 2023, then plummeted 99.93% in 2024.
  • 60 Degrees Pharmaceuticals' Interest Expenses stood at -$1.6 million in 2022, then skyrocketed by 100.34% to $5446.0 in 2023, then crashed by 73.89% to $1422.0 in 2024, then grew by 20.11% to $1708.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Interest Expenses are $1708.0 (Q3 2025), $1221.0 (Q2 2025), and $1790.0 (Q1 2025).